Juan Jaen

Dr Jaen has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded Arcus Biosciences together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1.25 billion. Previously, he was CSO and Senior Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Dr Jaen led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. From 1996 to 2006, Dr Jaen held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry. From 1983 to 1996, Dr Jaen held various scientific leadership positions at Parke-Davis/Warner-Lambert.